The European Commission has granted marketing authorization for Roclanda to reduce IOP in adults with primary open-angle glaucoma or ocular hypertension, according to a press release from Aerie Pharmaceuticals.
Roclanda (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution) is authorized for patients who have insufficient IOP reduction with prostaglandin or netarsudil monotherapy, the release said.
“The receipt of the EC marketing authorization for Roclanda, which is the only fixed-dose combination IOP-lowering therapy with a prostaglandin analogue that does not include a beta
Uncategorized